Published online before print August 15, 2002, doi: 10.1161/01.RES.0000033593.05545.7B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Molecular Medicine |
Regulation of Smooth Muscle Cell Differentiation by AT-Rich Interaction Domain Transcription Factors Mrf2
and Mrf2ß
From the Cardiovascular (M.W., M.D.L., C.-M.H., K.M., S.G., M.-E.L., M.K.J.) and Pulmonary and Critical Care (M.D.L.) Divisions, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Mukesh K. Jain, MD, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, TH1127, Boston, MA 02115. E-mail mjain{at}rics.bwh.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Despite the importance of vascular smooth muscle cells in the regulation of blood vessel function, the molecular mechanisms governing their development and differentiation remain poorly understood. Using an in vitro system whereby a pluripotent neural crest cell line (MONC-1) can be induced to differentiate into smooth muscle cells, we isolated a cDNA fragment that was robustly induced during this differentiation process. Sequence analysis revealed high homology to a partial cDNA termed modulator recognition factor 2 (Mrf2). Because the full-length cDNA has not been reported, we cloned the full-length Mrf2 cDNA by cDNA library screening and 5' rapid amplification of cDNA ends and identified two isoforms of Mrf2 (
[3.0 kb] and ß [3.7 kb]) that differ in the N-terminus but share the DNA-binding domain. Protein homology analysis suggests that Mrf2 is a member of the AT-rich interaction domain family of transcription factors, which are known to be critically involved in the regulation of development and cellular differentiation. Mrf2 and Mrf2ß are highly induced during in vitro differentiation of MONC-1 cells into smooth muscle cells, and Mrf2 is expressed in adult mouse cardiac and vascular tissues. To define the function of Mrf2, we overexpressed both isoforms in 3T3 fibroblast cells and observed an induction of smooth muscle marker genes, including smooth muscle -actin and smooth muscle 22. Furthermore, Mrf2 and Mrf2ß retarded cellular proliferation. These data implicate Mrf2 as a novel regulator of smooth muscle cell differentiation and proliferation.
Key Words: smooth muscle • differentiation • proliferation • transcription factors
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The vascular smooth muscle cell (SMC) is a critical cellular constituent of the blood vessel wall. In the adult blood vessel, vascular SMCs express a characteristic set of genes, exhibit a low proliferative index, and are involved in contraction and relaxation. In response to blood vessel wall injury, the vascular SMCs undergo a remarkable change in phenotype characterized by a decrease in contractile protein expression, reexpression of "fetal" smooth muscle (SM) genes, an increase in cellular proliferation, and an enhanced elaboration of extracellular matrix products.1 These phenotypic changes are important in the pathogenesis of occlusive vascular disease evident in a number of clinical disease entities, such as arteriosclerosis, restenosis after percutaneous revascularization, and transplant vasculopathy.1
It has been suggested that this response to injury recapitulates a genetic program normally instituted during fetal development.2,3 We reasoned that an understanding of normal mechanisms governing SM differentiation may allow one to modulate the SMC phenotype in disease states in a therapeutically beneficial manner. However, despite the importance of the SMC, the molecular mechanism(s) governing the physiological development of this cell and its response to pathological stimuli remain poorly understood. One of the principal reasons is the lack of an in vitro system for SMC differentiation. Previous studies have shown that primary mouse neural crest cells can be induced to differentiate into SMCs.4 Furthermore, we reported an in vitro system whereby a pluripotent neural crest cell line (MONC-1) could be forced to assume the morphological and genetic characteristic of SMCs.5 Differentiation can be initiated by a change in medium and results in the induction of SMC genes, such as SM -actin, SM22, calponin, APEG-1, and SM myosin heavy chain (SM1).
To identify factors that may regulate this process, we used differential mRNA display to identify transcripts that are differentially expressed in MONC-1 cells before and after SMC differentiation. We identified a cDNA fragment whose expression was induced <3 hours after the initiation of the SMC differentiation. Sequence analysis revealed high homology to a partial cDNA termed the modulator recognition factor 2 (Mrf2) gene.6,7 Because the full-length Mrf2 has not been reported, we cloned it and identified two isoforms. Protein homology analysis suggests that Mrf2 is a member of the AT-rich interaction domain (ARID) family of transcription factors.8 In the present study, we provide evidence that Mrf2 may serve as a regulator of SMC differentiation and proliferation.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture and Reagents
The mouse neural crest cell line, MONC-1,9 was kindly provided by David Anderson (California Institute of Technology, Pasadena, Calif) and cultured as described.5,10 SMC differentiation of MONC-1 cells was induced by applying medium 199 supplemented with 10% FBS (HyClone), 100 U/mL penicillin, 100 µg/mL streptomycin, and 25 mmol/L HEPES (pH 7.4), hereafter referred to as SMC differentiation medium (SMDM). Differentiation down the neuronal and glial pathways was performed as described.11 Rat aortic SM cells (RASMCs) were harvested from the thoracic aortas of adult male Sprague-Dawley rats (200 to 250 g; Zivic-Miller Co, Zelienople, Pa) by enzymatic digestion, according to the method of Gunther et al.12 NIH-3T3 cells, A10 cells, and A7r5 cells were obtained from American Type Culture Collection and cultured in DMEM supplemented with 10% FBS. Human aortic SMCs (HASMCs) and human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics. 293T cells were obtained from Dr Hamid Band (New England Medical Center, Boston, Mass) and maintained as described.13 Most of the media and the components of medium were obtained from Invitrogen. Animal care and procedures were approved by the Harvard Medical School Standing Committee on Animals and were performed in accordance with the guidelines of the American Association for Accreditation of Laboratory Animal Care (NIH).
RNA Extraction and Northern Analysis
Total RNA from cultured cells and mouse tissue was prepared by guanidinium isothiocyanate extraction and centrifugation through cesium chloride14 or by using an RNeasy RNA purification kit (Qiagen). Total RNA was fractionated on a 1.3% formaldehyde-agarose gel and transferred to nitrocellulose filters, which were hybridized with the appropriate [32P]dCTP-labeled probe by a random-primed kit (Stratagene). The hybridized filters were washed in 30 mmol/L sodium chloride, 3 mmol/L sodium citrate, and 0.1% SDS at 55°C and exposed to Kodak XAR film at -80°C. To correct for differences in RNA loading, the blots were hybridized with an 18S rRNA oligonucleotide probe. To detect specific mRNA expression of each Mrf2 isoform by Northern analysis, we prepared an Mrf2-specific probe in the 5' untranslated region of Mrf2 by polymerase chain reaction (PCR) with primers G9017 up (5'-CTGAGCCTCCTCGCAGCT-3') and G9017 low (5'-TTCCAGTCGCCAAACATCTG-3'). An Mrf2ß-specific probe (431 bp) was obtained by BamHI restriction digestion from the 5' coding region of Mrf2ß. Mouse SM -actin, mouse SM22, mouse calponin, and mouse GAPDH were prepared by a RT-PCR technique.
Differential mRNA Display
We prepared several RNA samples from undifferentiated MONC-1 cells and MONC-1 cells cultured in SMDM for 10, 24, and 96 hours. Differential display analysis of these mRNA samples was performed using the HIEROGLYPH mRNA Profile Kit for Differential Display Analysis (Genomyx). The expression levels of these cDNA fragments were compared in duplicate on polyacrylamide gels. Each fragment of interest was isolated from gel, reamplified, and analyzed.
5'-RACE
The 5' end of mouse Mrf2 was cloned by the 5' rapid amplification of cDNA ends (5'-RACE) system (Invitrogen) using mouse aortic RNA. Primers used were as follows: G9008-1, 5'-TCCTTTGAGCCACTGA-3', for reverse transcription; G9008-2, 5'-GAGCCACTGAAGGAATCTCT-3', for the initial PCR; and G9008-3, 5'-CGCCATTCCAGTCGCCAAA-3', for the nested PCR.
Cloning of Full-Length Mouse Mrf2 by Library Screening
Differentiation display product DD101 was used to screen a mouse 11-day embryo 5' stretch plus cDNA library (Clontech) according to the manufacturer’s protocol. Several clones were obtained, and a fragment from the most 3' cDNA clone was used to screen the library again. The sequences from these clones and 5'-RACE PCR product were assembled, and the full length of the Mrf2 isoforms was determined.
Computational Analysis
Sequence analysis was performed using Sequencher software (Gene Code Corp). Protein alignment and phylogenetic analysis were performed with the Clustal V algorithm included within the MegaAlign module of the Lasergene software package (DNASTAR).
Cloning of Full-Length hMrf2 by Sequencing Est Clones and GenBank Search
A homology search with reported human Mrf2 (hMrf2) fragment in the human Est database of the National Center for Biotechnology Information and The Institute for Genomic Research was performed, and two Est cDNA clones (zm02a05.r1 and THC558757) overlapping the hMrf2 cDNA were found. After sequencing the clone, zm02a05.r1 (American Type Culture Collection), we assembled those sequences and generated the 3060-bp partial human cDNA, which included the stop codon. To clone the 5' end of hMrf2, we searched the human genomic sequence with the mouse Mrf2 sequence and identified two nonoverlapping genomic fragments (NT_008797.9 and NT_033984.1) containing the entire hMrf2 coding region. We found an additional 507-bp 5' end of the hMrf2 cDNA sequence including the ATG translation start site, and we assembled the putative full length of hMrf2 cDNA.
Construction of Plasmids
Mouse Mrf2 mammalian expression vectors were constructed by PCR in two steps. First, the 1.3-kb 5' portion of Mrf2 and the 2.1-kb portion of Mrf2ß were amplified from MONC-1 RNA by RT-PCR using PfuTurbo DNA polymerase (Stratagene) with primers GK19 and GK24 and primers GK25 and GK24, respectively. The 1.5-kb 3' portion of common Mrf2 was amplified from MONC-1 RNA with primer GK23 and primer GK21. These amplified fragments were cloned into the pCR-BluntII TOPO vector (Invitrogen). Next, two parts of cloned fragments were combined and subcloned into the mammalian expression vector pcDNA3.1(-) (Invitrogen). The primer sequences to construct these plasmids are as follows: GK19, 5'-GCTCTAGAGTTTGGCGACTGGAATGGCG-3'; GK21, 5'-GCCTCGAGGGTGCAATGGACCACACCATT-3'; GK23, 5'-TGA- GAACCACGGACTTAACTA-3'; GK24, 5'-ATAGGGATAGCTGCT- GGAGA-3'; and GK25, 5'-GCTCTAGAACGTCGAGATGGAGCC-3'.
To construct the expression plasmid Mrf2-c-myc and Mrf2ß-c-myc, we added in frame a DNA sequence encoding a c-Myc peptide tag (EQKLISEED) to the open reading frame at the 3' end of Mrf2 and Mrf2ß-pcDNA3.1 by PCR techniques. We generated truncated Mrf2ß(
C493)-c-myc-His and Mrf2(C493)-c-myc-His by subcloning the 5' 2.1-kb fragment of Mrf2ß and the 5' 1.4-kb fragment of Mrf2, respectively, into pcDNA3.1/Myc-His(-) A. Both constructs lack 493 amino acids of the C-terminus. We also constructed truncated Mrf2ß(C493)-flag by adding in frame a DNA sequence encoding a flag tag to the 5' end of the open reading frame in pcDNA3.1. All plasmids were verified by sequencing.
Immunofluorescent Staining
NIH-3T3 cells grown on the glass slides were transiently transfected with the Mrf2ß-myc–expressing plasmid using Fugene6 (Roche). Forty-eight hours after transfection, the cells were fixed, stained using an anti–c-Myc monoclonal antibody (9E10, Oncogene), and visualized with a fluorescence microscope as described.15 Nuclei were counterstained with bis-benzimide (Molecular Probes).
Electrophoretic Mobility Shift Analysis
Nuclear extracts were prepared according to the method of Ritzenthaler et al16 with minor modifications. Double-stranded oligonucleotide probes (5'-AGCTCCACAATACCAGGA-3') synthesized according to the sequence of the Mrf2 core binding element (underlined)6 were [32P]ATP-labeled by T4 polynucleotide kinase (New England Biolabs). The reaction mixtures were incubated at 4°C for 3 hours in a total volume of 20 µL containing 10 mmol/L Tris-HCl (pH 7.5), 50 mmol/L KCl, 1 mmol/L DL-dithiothreitol, 5% glycerol, 0.5 µg of poly dI-dC (Amersham), 2.0x104 cpm of labeled probe, and 20 µg of nuclear extract. The mixtures were analyzed by 4% native polyacrylamide gel electrophoresis in 0.25x TBE buffer (containing 22 mmol/L Tris base, 22 mmol/L boric acid, and 0.5 mmol/L EDTA) at 4°C. A 250-fold excess of specific or nonspecific oligonucleotide was used for competition experiments. The sequence of double-stranded oligonucleotide used as competitor was as follows: mutated Mrf2 core binding element, 5'-AGCTCCACAcgACCAGGA-3'; CArG-binding element,17 5'-CTTTCCCCAAATATGGAGCCTG-3'; and nonspecific oligonucleotide, 5'-AGCTGTCAGCCCATGTGGCGTGGCCGCA-3'.
Retroviral Constructs and Transduction
The GFP-RV retrovirus vector and the Phoenix-Eco packaging cell line were obtained from Dr K. Murphy (Washington University School of Medicine, St. Louis, Mo).18,19 Full-length Mrf2 and Mrf2ß cDNA fragments amplified by PCR were subcloned into GFP-RV vectors. These expression vectors simultaneously express Mrf2 and GFP cDNA. Transfection of the packaging cell line and retroviral transductions were performed as described.19 Infection of NIH-3T3 cells in the presence of 4 µg/mL hexadimethrine bromide (Polybrene) allowed for 100% infectivity.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Identification of Mouse Mrf2
and Mrf2ßA differential display was used to identify cDNAs, which are regulated during SMC differentiation by using the MONC-1 system. Our criteria are as follows: (1) expression of the gene should be induced during MONC-1 cell differentiation, and (2) the gene should be also expressed in the adult mouse aorta. A number of cDNAs were isolated and sequenced, and their differential expressions were verified. A computer-assisted GenBank search revealed that one of the identified cDNAs (Figure 1A, DD101) was the mouse homologue of a partial human cDNA Mrf2 (hMrf2).7 Although the full-length cDNA of hMrf2 had not been reported at that time, binding site selection studies and crystal structure analysis using the DNA-binding domain revealed that this factor was able to bind to the A/T-rich consensus sequence AATA(C/T).6,7 We used a combination of 5'-RACE and cDNA library screening to clone the full-length mouse Mrf2 cDNA (Figure 1A). These studies revealed two forms, which differ at the 5' end but are identical from Ala245 (indicated by asterisk in Figure 1B) to the C-terminus. The shorter product is termed Mrf2
, whose open reading frame is 2835 bp, with a predicted protein size of 104 kDa. The longer product, termed Mrf2ß, is a 3564-bp open reading frame with a predicted size of 131 kDa.
|
Homology and Genetic Analysis of Mrf2
Using the mouse Mrf2 cDNA as a template, we assembled a putative cDNA sequence of hMrf2 from human Est clones, a 5'-RACE product, and the human genomic sequence. The amino acid and cDNA nucleotide sequences 2were well conserved between mouse and human (amino acid, 87% identity; nucleotide, 85%). We also identified an 83-amino-acid domain (underlining in Figure 1B) that has high homology to ARID8 and another 73-amino-acid domain (dashed underlining in Figure 1B) in Mrf2ß, which has a homology to the bromo-adjacent homology (BAH) domain.20 The sequence of the ARID domain was completely conserved between mice and humans. Examination of the mouse and human genome database reveals that there is one mouse clone (NW_000027.1) that contains all the coding region of mouse Mrf2 and two nonoverlapped clones (NT_008797.9 and NT_033984.1) that contain all the coding region of hMrf2. In both species, these clones are located in chromosome 10. We deduced the genomic structure of both mouse Mrf2 and hMrf2 from these clone sequences in GenBank and found that both species have almost identical genomic structures with 11 exons (Figure 1C). Exons 5 to 11 constitute Mrf2 cDNA, whereas exons 1 to 4 and 6 to 11 constitute Mrf2ß (Figure 1C). Finally, sequence alignment and phylogenetic analyses suggest that Mrf1 and Mrf2 form a distinct subclass of the ARID family of transcription factors (Figures 2A and 2B).
|
Cellular and Tissue Expression of Mrf2
Mrf2 was identified on the basis of its differential expression in undifferentiated versus differentiated MONC-1 cells. We verified this by Northern blot analysis using cDNA fragments specific to Mrf2 and Mrf2ß. Both Mrf2 and Mrf2ß were induced during MONC-1 differentiation (Figure 3A). The expression of Mrf2 is more restricted because induction was not observed when MONC-1 cells were differentiated down the neuronal pathway. Both isoforms were also expressed in cultured primary RASMCs and HASMCs (Figure 3B) and the SMC line A7r5 but not in HUVECs. To determine the tissue expression of Mrf2 in adult mice, we isolated total RNA from a number of adult mouse tissues and subjected them to Northern analysis by using the isoform-specific probes. These studies revealed distinct expression patterns for the two isoforms. Mrf2 mRNA was detected in the aorta, heart, and lung. In contrast, low Mrf2ß mRNA expression was detected in the lung and spleen, and very low expression was detected in the aorta and kidney (Figure 3C).
|
Mrf2 Is a Nuclear Protein and Binds to A/T-Rich Sequences
Analysis of the Mrf2 cDNA revealed the presence of a potential nuclear localization signal in the region shared by Mrf2 and Mrf2ß (Figure 1B, bold). To assess cellular localization, we cloned the full length of both isoforms bearing a C-terminal c-myc tag into a mammalian expression vector and transiently transfected into NIH-3T3 cells. Immunocytochemical analysis using an anti-myc antibody revealed that Mrf2 showed only nuclear localization (Figure 4A). A similar nuclear localization pattern was observed with Mrf2ß (data not shown).
|
B binding sequence was used as a nonspecific competitor. One microliter of antiserum to Flag, serum response factor (SRF), and c-myc (NS indicates nonspecific antiserum) was incubated with nuclear extracts to show the supershift of the DNA and protein complexes. The DNA-protein complex is indicated by an arrow.
The 108-amino-acid ARID domain of Mrf2 is shown to bind AATA(C/T) as a consensus binding site.6 This is of interest in SM biology, because A/T-rich sequences, termed CArG boxes, have been implicated as being critical in the regulation of SMC genes, such as SM -actin, 21 SM22,17 calponin,22 and the SM123 promoters. To assess the ability of Mrf2 to bind these sequences, we performed electrophoretic mobility shift assays using nuclear extracts from 293T cells transfected with several Mrf2 constructs. We did not observe any specific retarded bands in the presence of full-length Mrf2 and Mrf2ß. However, C-terminal truncations of both isoforms, Mrf2ß(C493) and Mrf2(C493), which retain the ARID DNA-binding domain, were able to bind to the Mrf2-binding site. To verify the specificity of this band, competition and supershift studies were performed. As shown in Figure 4C, the binding of Mrf2ß(C493) could be competed away with an identical competitor probe but not a mutated oligomer. Interestingly, an oligomer containing the CArG box was also able to compete for binding, suggesting that the DNA-binding domain of Mrf2 may bind to the ArG element (Figure 4C). This DNA-protein complex could be supershifted in the presence of an anti-Flag antibody but not an anti–serum response factor or nonspecific antibody (anti–c-myc). Identical results were seen with Mrf2. These data suggest that Mrf2 and Mrf2ß can bind to an A/T-rich consensus sequence.
Overexpression of Mrf2 Induces SMC Gene Expression
The induction of Mrf2 isoforms with MONC-1 differentiation raised the possibility that these factors may induce SMC marker genes. To test this hypothesis, we assessed the ability of both Mrf2 and Mrf2ß (Figure 5) to regulate the expression of SM markers in a heterologous fibroblast cell line, NIH-3T3. Cells infected with empty virus (control) or uninfected cells were used as controls. We did not observe any evidence of toxicity from overexpression of any of these constructs. In contrast to control, overexpression of either Mrf2 or Mrf2ß induced the expression of SMC genes, such as SM -actin and SM22 (Figure 5). We did not observe any effect on the expression of calponin (Figure 5) or SM1 (data not shown). These data suggest that both Mrf2 isoforms can induce certain SMC genes, such as SM -actin and SM22.
|
Overexpression of Mrf2 Retards Cell Proliferation
Cellular differentiation is characteristically accompanied by a reduction in cellular proliferation. To assess whether Mrf2 can regulate cellular proliferation, 3T3 fibroblast cells were retrovirally infected, and the number of cells was counted on 2 days and 4 days after infection. We did not observe any evidence of cellular toxicity. Representative experimental data are shown (Figure 6), and similar results were observed in three independent experiments. Cells overexpressing either Mrf2 or Mrf2ß exhibited an 
30% to 40% reduction in cell number compared with empty vector (Figure 6). To exclude the possibility that the reduction in cellular proliferation was due to apoptosis, we tested for caspase-3 activity. No statistically significant difference was observed between uninfected cells, empty virus–infected cells, and Mrf2 and Mrf2ß retrovirus–infected cells. In contrast, treatment of cells with staurosporine resulted in a significant apoptotic effect24 (data not shown). Taken together, these data suggest that both Mrf2 isoforms may induce a differentiated and quiescent state of SMCs.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Using differential display, we identified Mrf2 as a nuclear factor induced during MONC-1 cell differentiation into SMCs. Although a partial cDNA of Mrf2 had been previously published,6,7,25 the full-length cDNA had not been reported. In the present study, we identified two isoforms of Mrf2 that differ by 245 amino acids at the 5' end. We also found that overexpression of both isoforms potently induces the expression of SMC markers and retards cellular proliferation.
A GenBank search revealed that Mrf2 has a high homology to a cDNA termed DESRT (accession No. AF169968).26,27 Interestingly, the DESRT cDNA terminates at base pair 2178 because of a single nucleotide insertion, which results in a frame shift. Given that the predicted amino acids of DESRT and Mrf2 are similar, it is likely that they are very closely related gene or splice variants. The expression patterns of both Mrf2 isoforms are distinct, suggesting possible tissue-specific roles. With respect to SMCs, both isoforms are induced with differentiation. However, expression of the isoform is induced only during SMC differentiation but not after neuronal cell differentiation. Furthermore, this isoform is strongly expressed in the aorta, suggesting that it is likely the dominant isoform in SMCs.
The DNA-binding domain of Mrf2 bears high homology to the ARID family of transcription factors (Figures 2A and 2B). Nuclear magnetic resonance studies showed that the structure of the Mrf2 domain is significantly different from the known DNA-binding domain and consists of helices and loops but not any ß strands.7 ARID is shared by several proteins in a variety of organisms, such as yeast, plants, Drosophila, and vertebrates.8 Mrf2 does not contain jmjN or jmjC motifs28 or REKLES domains,7 which are shared by other members of the ARID family protein. Although the full length of Mrf1 is not reported, Mrf1 and Mrf2 may constitute a distinct subgroup of ARID proteins (Figure 2B). The specific roles of the ARID domain have not been fully elucidated, but ARID family proteins are involved in a number of biological processes, including embryonic development,29 cell lineage gene regulation,30 and cell cycle control.31 We also identified in Mrf2ß a region bearing homology to the BAH domain, which has been implicated in chromatin regulation.20 Because ARID family proteins are repeatedly suggested to be involved in chromatin regulation,30,32,33 some aspect of Mrf2 function may involve chromatin modification and regulation.
In most biological systems, cellular differentiation is accompanied by a reduction in cellular growth rates. The induction of Mrf2 isoforms during SMC differentiation raised the possibility of a role in cellular differentiation. To formally address this possibility, we overexpressed both Mrf2 isoforms and assessed the effects on the expression of SMC differentiation markers and cellular proliferation. Indeed, we observed that overexpression of both Mrf2 isoforms induced the expression of certain classical SMC markers and retarded cellular proliferation (Figures 5 and 6). Specifically, we observed that Mrf2 overexpression induced SM -actin and SM22 but not other markers, such as calponin, SM1, or smoothelin (Figure 5 and data not shown). The expressions of SM -actin and SM22 are early markers of the SMC lineage but can also been seen in the conversion of fibroblasts into myofibroblasts. As such, Mrf2 may be involved in the early stages of differentiation into SMCs and/or into myofibroblasts. The induction of Mrf2 within hours of culturing MONC-1 cells in SM differentiation medium supports a role for these factors in the early stages of differentiation into SMCs. Previous studies highlight the importance of a cis-acting element, termed the CArG box, in the regulation of most SM genes, such as SM -actin,21 SM22,17 calponin,22 and the SM123 promoters. We found that the CArG box oligomer derived from the SM22 promoter competed away Mrf2 binding in gel-shift studies, suggesting that Mrf2 may bind to this element (Figure 4B). However, we were unable to show direct Mrf2 binding to the CArG box in gel-mobility shift assays using in vitro–transcribed and in vitro–translated products or recombinant protein, thereby supporting a non–CArG-dependent mechanism. Alternatively, it is still possible that Mrf2 may bind the CArG element in vivo in the presence of critical cofactors or in the appropriate DNA context. These issues are the focus of ongoing studies.
|
Acknowledgments |
|---|
This study was supported by grants from the NIH (HL-57664 to Drs Lee and Jain and HL-03747 and HL-69477 to Dr Jain) and from the American Heart Association (Nos. 0060159T and 0250030N to Dr Jain). The sequences of the mouse Mrf2
and Mrf2ß cDNAs have been deposited in the GenBank with accession Nos. AF401550 and AF280065, respectively. |
Footnotes |
|---|
Dr Lee died April 10, 2000. 
Received March 8, 2002; revision received July 16, 2002; accepted August 2, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995; 75: 487–517.
2. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science. 1996; 272: 689–693.[Abstract]
3. Kuro-o M, Nagai R, Nakahara K, Katoh H, Tsai RC, Tsuchimochi H, Yazaki Y, Ohkubo A, Takaku F. cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem. 1991; 266: 3768–3773.
4. Shah NM, Groves AK, Anderson DJ. Alternative neural crest cell fates are instructively promoted by TGF superfamily members. Cell. 1996; 85: 331–343.[CrossRef][Medline] [Order article via Infotrieve]
5. Jain MK, Layne MD, Watanabe M, Chin MT, Feinberg MW, Sibinga NE, Hsieh C-M, Yet S-F, Stemple DL, Lee M-E. In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells. J Biol Chem. 1998; 273: 5993–5996.
6. Whitson RH, Huang T, Itakura K. The novel Mrf-2 DNA-binding domain recognizes a five-base core sequence through major and minor-groove contacts. Biochem Biophys Res Commun. 1999; 258: 326–331.[CrossRef][Medline] [Order article via Infotrieve]
7. Yuan YC, Whitson RH, Liu Q, Itakura K, Chen Y. A novel DNA-binding motif shares structural homology to DNA replication and repair nucleases and polymerases. Nat Struct Biol. 1998; 5: 959–964.[CrossRef][Medline] [Order article via Infotrieve]
8. Kortschak RD, Tucker PW, Saint R. ARID proteins come in from the desert. Trends Biochem Sci. 2000; 25: 294–299.[CrossRef][Medline] [Order article via Infotrieve]
9. Rao MS, Anderson DJ. Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells. J Neurobiol. 1997; 32: 722–746.[CrossRef][Medline] [Order article via Infotrieve]
10. Stemple DL, Anderson DJ. Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell. 1992; 71: 973–985.[CrossRef][Medline] [Order article via Infotrieve]
11. Sommer L, Shah N, Rao M, Anderson DJ. The cellular function of MASH1 in autonomic neurogenesis. Neuron. 1995; 15: 1245–1258.[CrossRef][Medline] [Order article via Infotrieve]
12. Gunther S, Alexander RW, Atkinson WJ, Gimbrone MA Jr. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol. 1982; 92: 289–298.
13. Ota S, Hazeki K, Rao N, Lupher ML Jr, Andoniou CE, Druker B, Band H. The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase. J Biol Chem. 2000; 275: 414–422.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
15. Layne MD, Endege WO, Jain MK, Yet S-F, Hsieh C-M, Chin MT, Perrella MA, Blanar MA, Haber E, Lee M-E. Aortic carboxypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell differentiation. J Biol Chem. 1998; 273: 15654–15660.
16. Ritzenthaler JD, Goldstein RH, Fine A, Lichtler A, Rowe DW, Smith BD. Transforming-growth-factor-ß activation elements in the distal promoter regions of the rat 1 type I collagen gene. Biochem J. 1991; 280: 157–162.[Medline]
[Order article via Infotrieve]
17. Kim S, Ip HS, Lu MM, Clendenin C, Parmacek MS. A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol Cell Biol. 1997; 17: 2266–2278.[Abstract]
18. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000; 100: 655–669.[CrossRef][Medline] [Order article via Infotrieve]
19. Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, Murphy KM. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity. 1998; 9: 745–755.[CrossRef][Medline] [Order article via Infotrieve]
20. Callebaut I, Courvalin JC, Mornon JP. The BAH (bromo-adjacent homology) domain: a link between DNA methylation, replication and transcriptional regulation. FEBS Lett. 1999; 446: 189–193.[CrossRef][Medline] [Order article via Infotrieve]
21. Mack CP, Owens GK. Regulation of smooth muscle -actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions. Circ Res. 1999; 84: 852–861.
22. Miano JM, Carlson MJ, Spencer JA, Misra RP. Serum response factor-dependent regulation of the smooth muscle calponin gene. J Biol Chem. 2000; 275: 9814–9822.
23. Manabe I, Owens GK. CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J Clin Invest. 2001; 107: 823–834.[Medline] [Order article via Infotrieve]
24. Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak TW, Ingram AJ. Akt is activated in response to an apoptotic signal. J Biol Chem. 2001; 276: 30461–30466.
25. Yuan YC, Whitson RH, Itakura K, Chen Y. Resonance assignments of the Mrf-2 DNA-binding domain. J Biomol NMR. 1998; 11: 459–460.[CrossRef][Medline] [Order article via Infotrieve]
26. Ristevski S, Tam PPL, Kola I, Hertzog P. Desrt, an AT-rich interaction domain family transcription factor gene, is an early marker for nephrogenic mesoderm and is expressed dynamically during mouse limb development. Mech Dev. 2001; 104: 139–142.[CrossRef][Medline] [Order article via Infotrieve]
27. Lahoud MH, Ristevski S, Venter DJ, Jermiin LS, Bertoncello I, Zavarsek S, Hasthorpe S, Drago J, de Kretser D, Hertzog PJ, Kola I. Gene targeting of desrt, a novel arid class DNA-binding protein, causes growth retardation and abnormal development of reproductive organs. Genome Res. 2001; 11: 1327–1334.
28. Balciunas D, Ronne H. Evidence of domain swapping within the jumonji family of transcription factors. Trends Biochem Sci. 2000; 25: 274–276.[CrossRef][Medline] [Order article via Infotrieve]
29. Treisman JE, Luk A, Rubin GM, Heberlein U. Eyelid antagonizes wingless signaling during Drosophila development and has homology to the Bright family of DNA-binding proteins. Genes Dev. 1997; 11: 1949–1962.
30. Herrscher RF, Kaplan MH, Lelsz DL, Das C, Scheuermann R, Tucker PW. The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev. 1995; 9: 3067–3082.
31. Fattaey AR, Helin K, Dembski MS, Dyson N, Harlow E, Vuocolo GA, Hanobik MG, Haskell KM, Oliff A, Defeo-Jones D. Characterization of the retinoblastoma binding proteins RBP1 and RBP2. Oncogene. 1993; 8: 3149–3156.[Medline] [Order article via Infotrieve]
32. Peterson CL. Multiple SWItches to turn on chromatin? Curr Opin Genet Dev. 1996; 6: 171–175.[CrossRef][Medline] [Order article via Infotrieve]
33. Agulnik AI, Mitchell MJ, Mattei MG, Borsani G, Avner PA, Lerner JL, Bishop CE. A novel X gene with a widely transcribed Y-linked homologue escapes X-inactivation in mouse and human. Hum Mol Genet. 1994; 3: 879–884.
This article has been cited by other articles:
 |
|
 |
|
  M. A. Saleem, J. Zavadil, M. Bailly, K. McGee, I. R. Witherden, H. Pavenstadt, H. Hsu, J. Sanday, S. C. Satchell, R. Lennon, et al. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells Am J Physiol Renal Physiol, October 1, 2008; 295(4): F959 - F970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamakawa, R. H. Whitson, S.-L. Li, and K. Itakura Modulator Recognition Factor-2 Is Required for Adipogenesis in Mouse Embryo Fibroblasts and 3T3-L1 Cells Mol. Endocrinol., February 1, 2008; 22(2): 441 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Wang, L.-H. Su, and C.-H. Sun A Novel ARID/Bright-like Protein Involved in Transcriptional Activation of Cyst Wall Protein 1 Gene in Giardia lamblia J. Biol. Chem., March 23, 2007; 282(12): 8905 - 8914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Spin, S. Nallamshetty, R. Tabibiazar, E. A. Ashley, J. Y. King, M. Chen, P. S. Tsao, and T. Quertermous Transcriptional profiling of in vitro smooth muscle cell differentiation identifies specific patterns of gene and pathway activation Physiol Genomics, November 17, 2004; 19(3): 292 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Owens, M. S. Kumar, and B. R. Wamhoff Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease Physiol Rev, July 1, 2004; 84(3): 767 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brunelli, E. Tagliafico, F. G. De Angelis, R. Tonlorenzi, S. Baesso, S. Ferrari, M. Niinobe, K. Yoshikawa, R. J. Schwartz, I. Bozzoni, et al. Msx2 and Necdin Combined Activities Are Required for Smooth Muscle Differentiation in Mesoangioblast Stem Cells Circ. Res., June 25, 2004; 94(12): 1571 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, A. M. Hoggatt, and B. P. Herring Activation of the Smooth Muscle-specific Telokin Gene by Thyrotroph Embryonic Factor (TEF) J. Biol. Chem., April 16, 2004; 279(16): 15929 - 15937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, D.-Z. Wang, Z. Wang, J. A. Richardson, and E. N. Olson The serum response factor coactivator myocardin is required for vascular smooth muscle development PNAS, August 5, 2003; 100(16): 9366 - 9370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, D.-Z. Wang, G. C. T. Pipes, and E. N. Olson Myocardin is a master regulator of smooth muscle gene expression PNAS, June 10, 2003; 100(12): 7129 - 7134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kumar and G. K. Owens Combinatorial Control of Smooth Muscle-Specific Gene Expression Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 737 - 747. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||